

---

## Lytix Q4 2023 - All Eyes on Verrica's Phase II

Lytix's partner Verrica fully recruited its phase II study in basal cell carcinoma in January, with a topline readout expect in H1 2024. This will be a major catalyst that can change the investment case. Lytix will focus the future development of LTX-315 on the neoadjuvant instead of refractory setting, which increases its sales potential, but will also mean a longer time to the market.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Lytix Q4 2023 - All Eyes on Verrica's Phase II](#)